Argatroban is a direct thrombin inhibitor approved for anticoagulation in heparin-induced
thrombocytopenia (HIT; in several countries) and in patients with or at risk of HIT undergoing …

Argatroban, a highly selective direct thrombin inhibitor, is indicated for use as an
anticoagulant for the treatment and prophylaxis of thrombosis in patients with heparin …

Heparin-induced thrombocytopenia (HIT) is a rare but potentially severe complication of
heparin therapy that is strongly associated with venous and arterial thrombosis (HIT and …

Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or
treatment of thrombosis in heparin-induced thrombocytopenia (HIT) and for patients with or …

When heparin-induced thrombocytopenia (HIT) is reasonably suspected, all heparin
exposures should be eliminated and an alternative nonheparin anticoagulant expeditiously …

Argatroban is a synthetic direct thrombin inhibitor. It is indicated for use in patients with
heparin-induced thrombocytopenia (HIT). The greatest experience is in prevention and …

Heparin-induced thrombocytopenia (HIT) is an immunoglobulin-mediated serious
complication of heparin therapy characterized by thrombocytopenia and high risk for venous …

The elimination of all heparin sources and the initiation of alternative anticoagulation are
recommended for treating patients with heparin-induced thrombocytopenia (HIT), whether or …

Background: Heparin-induced thrombocytopenia (HIT) is a serious, life-threatening
complication which occurs in 1–3% of patients receiving heparin. Patients with untreated HIT …

OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, adverse events, and
cost of argatroban in the prevention and treatment of thromboembolism in patients with …